Investor's Business Daily on MSN4d
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...
Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027
Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.
Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Behind the Scenes of Moderna's Latest Options Trends
Present Market Standing of Moderna Trading volume stands at 5,013,059, with MRNA's price down by -2.52%, positioned at $68.1. RSI indicators show the stock to be may be approaching oversold. Earnings ...
Moderna Stock Keeps Falling. An Analyst's Downgrade Isn't Helping
Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.
Down 13% in 1 Day, Is Moderna Stock in Trouble?
Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is ...
Moderna forecasts lower sales next year, shares near four-year low
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...
Moderna lays out plan to slice research and development spending
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...
STAT8d
Moderna touts research progress as it cuts R&D spending by $1.1 billion
After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.
Moderna Inc. stock underperforms Friday when compared to competitors
Shares of Moderna Inc. MRNA slipped 3.43% to $65.69 Friday, on what proved to be an all-around mixed trading session for the ...